IMMPLACATE is a preclinical stage cell therapy company focusing on developing educated mesenchymal cells (EMCs) for the treatment of unwanted immune responses. The company's pioneering approach aims to address the unmet needs of patients with acute and chronic immune disorders, who face heightened mortality risks and diminished quality of life. Furthermore, the limitations and potential risks associated with current pharmaceutical options underscore the urgency for innovative and safer alternatives. Founded in 2017, IMMPLACATE's mission revolves around leveraging science-based EMC therapy to enhance the wellbeing of individuals battling immune-related conditions. However, detailed information regarding specific industries, headquarters, past investments, and notable investors is currently unavailable.
There is no investment information
We care about your data, and we'd love to use cookies make your experience better.
